RE:AEZS q1 fins due May 15lscfa wrote: Will CZO wait until May 30 per TSXV rules or man up and follow Nasdaq rules?
Bigger question: Who is behind the ~2.75 million shares that has been bid for CZO? Is Bloom Burton going to initiate coverage? What could the target price be? Will H.C. Wainwright also initiate new coverage? H.C. Wainwright had a C$100 million market cap target for AEZS before the merger. What could the target price be for the merged company? Having shown no adverse events to 480mg and given the historical data for avenanthramide how clear is the path to a viable drug now? Given the 5X PGX scale-up is "almost complete" with three production runs completed and that CZO said this 5X scale-up would provide materials for potential partners is there a potential partnership announcement looming as the 10X scale-up is also expected to be commissioned in the next 5 months. What will it look like? Will AEZS's diagnostic test be the first standalone test in the industry? Data is expected in Q3. What will a deal be worth given previous deals? Are key pipeline findings for AEZS soon to be announced? Data from Harvard, which has worked on other NMSOD drugs, was expected very soon in October. Regulatory meetings were also to be scheduled for another drug who could clear a regulatory path.